Zenas BioPharma, Inc. IPO Advisory
Share this IPO Profile:Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
| Zenas BioPharma, Inc. | ZBIO - NASDAQ |
$16.00-$18.00 | $17.00 | $18.35 | 13.2 million | 9/13/2024 |
| Morgan Stanley, Jefferies, Citigroup, Guggenheim Securities | ||||||
Co-Manager(s): | ||||||
| Health Care | ||||||
Filing(s): Filed 2024-08-22 Terms Added 2024-09-06 | ||||||
Zenas BioPharma, Inc. Quote & Chart - Click for current quote - ZBIO
IPO Boutique aggregates information on public companies and private companies, such as "ZBIO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
About Zenas BioPharma, Inc. (adapted from Zenas BioPharma, Inc. prospectus):
They are a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
They are a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative immunology-based therapies for patients in need.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "ZBIO" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.